Entrada Therapeutics TRDA Stock
Entrada Therapeutics Price Chart
Entrada Therapeutics TRDA Financial and Trading Overview
| Entrada Therapeutics stock price | 7.15 USD |
| Previous Close | 7.09 USD |
| Open | 7.17 USD |
| Bid | 5.22 USD x 200 |
| Ask | 8.93 USD x 200 |
| Day's Range | 6.91 - 7.37 USD |
| 52 Week Range | 4.93 - 16.45 USD |
| Volume | 274.21K USD |
| Avg. Volume | 365.7K USD |
| Market Cap | 274.46M USD |
| Beta (5Y Monthly) | -0.259 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.75 USD |
TRDA Valuation Measures
| Enterprise Value | 49.65M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.1709292 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 47.832302 |
| Price/Book (mrq) | 0.8313735 |
| Enterprise Value/Revenue | 8.653 |
| Enterprise Value/EBITDA | -0.288 |
Trading Information
Entrada Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.259 |
| 52-Week Change | -0.14% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 16.45 USD |
| 52 Week Low | 4.93 USD |
| 50-Day Moving Average | 9.34 USD |
| 200-Day Moving Average | 9.45 USD |
TRDA Share Statistics
| Avg. Volume (3 month) | 365.7K USD |
| Avg. Daily Volume (10-Days) | 240.28K USD |
| Shares Outstanding | 38.82M |
| Float | 19.5M |
| Short Ratio | 2.52 |
| % Held by Insiders | 12.31% |
| % Held by Institutions | 78.39% |
| Shares Short | 1.73M |
| Short % of Float | 6.90% |
| Short % of Shares Outstanding | 4.44% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -4834.62% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.84% |
| Return on Equity (ttm) | -48.28% |
Income Statement
| Revenue (ttm) | 5.74M USD |
| Revenue Per Share (ttm) | 0.14 USD |
| Quarterly Revenue Growth (yoy) | -95.70% |
| Gross Profit (ttm) | -135811008 USD |
| EBITDA | -172556000 USD |
| Net Income Avi to Common (ttm) | -166118000 USD |
| Diluted EPS (ttm) | -4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 254.86M USD |
| Total Cash Per Share (mrq) | 7.07 USD |
| Total Debt (mrq) | 49.75M USD |
| Total Debt/Equity (mrq) | 18.37 USD |
| Current Ratio (mrq) | 13.903 |
| Book Value Per Share (mrq) | 8.504 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -131700000 USD |
| Levered Free Cash Flow (ttm) | -75381376 USD |
Profile of Entrada Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | One Design Center Place |
| ZIP | 02210 |
| Phone | 857 520 9158 |
| Website | https://www.entradatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 152 |
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Q&A For Entrada Therapeutics Stock
What is a current TRDA stock price?
Entrada Therapeutics TRDA stock price today per share is 7.15 USD.
How to purchase Entrada Therapeutics stock?
You can buy TRDA shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Entrada Therapeutics?
The stock symbol or ticker of Entrada Therapeutics is TRDA.
Which industry does the Entrada Therapeutics company belong to?
The Entrada Therapeutics industry is Biotechnology.
How many shares does Entrada Therapeutics have in circulation?
The max supply of Entrada Therapeutics shares is 38.82M.
What is Entrada Therapeutics Price to Earnings Ratio (PE Ratio)?
Entrada Therapeutics PE Ratio is now.
What was Entrada Therapeutics earnings per share over the trailing 12 months (TTM)?
Entrada Therapeutics EPS is -4 USD over the trailing 12 months.
Which sector does the Entrada Therapeutics company belong to?
The Entrada Therapeutics sector is Healthcare.
Entrada Therapeutics TRDA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25695.73 USD — |
+0.42
|
2.92B USD — | 25565.07 USD — | 25749.06 USD — | — - | 2.92B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2316.99 USD — |
+0.29
|
— — | 2308.2 USD — | 2324.3 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1205.54 USD — |
+1.76
|
— — | 1192.12 USD — | 1207 USD — | — - | — — |
- {{ link.label }} {{link}}